Anti-Mouse IFNβ – Purified in vivo GOLD™ Functional Grade

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

N This antibody is recommended for neutralization of mouse IFN-β bioactivity

Armenian Hamster Anti-Mouse IFNβ (Clone MIB-5E9.1) recognizes Mouse IFNβ. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Fibroblasts & epithelial cells

Interferons (IFN) consist of two classes. The type I IFN class consists of 20 highly similar IFN-α proteins and a single IFN-ß protein. The second class, type II IFN, consists of a single protein, IFN-γ. IFN-α and IFN-ß signal through the same cell surface receptor IFNAR1 and have a similar range of biological activities including antiviral and antiproliferative activity. The type I IFNs also influence activation, growth and differentiation of T cells, B cells, macrophages, NK cells and other cell types such as endothelial cells and fibroblasts. IFN-ß has recently proven to be beneficial in patients with multiple sclerosis and could also be a potential therapy for rheumatoid arthritis. It is unclear what cellular mechanisms are involved in IFN-ß’s therapeutic effects, but they may be caused by a restoration of balance between pro- and anti-inflammatory cytokines.

IFNα/βR (IFNAR-1, IFNAR-2)